Literature DB >> 10471824

Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis.

J Just1, C Moog-Lutz, A Houzel-Charavel, S Canteloup, A Grimfeld, V Witko-Sarsat, Y E Cayre.   

Abstract

Proteinase 3 (PR3), a serine proteinase which can degrade lung tissue, is present in the cystic fibrosis (CF) sputum. In the present study, PR3 protein and mRNA expression was determined in circulating neutrophils and monocytes. CF neutrophils contained similar PR3 concentrations as healthy controls and poorly expressed PR3 mRNA. In contrast, CF monocytes showed significantly higher PR3 concentrations than controls, together with an upregulation of PR3 mRNA expression especially during pulmonary exacerbation. Interestingly, antibiotic treatment fully abrogated PR3 mRNA expression and decreased PR3 protein in monocytes. Our findings highlight a potential role of monocyte-derived PR3 in CF-associated airway inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471824     DOI: 10.1016/s0014-5793(99)01098-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis.

Authors:  Arnaud Millet; Katherine R Martin; Francis Bonnefoy; Philippe Saas; Julie Mocek; Manal Alkan; Benjamin Terrier; Anja Kerstein; Nicola Tamassia; Senthil Kumaran Satyanarayanan; Amiram Ariel; Jean-Antoine Ribeil; Loïc Guillevin; Marco A Cassatella; Antje Mueller; Nathalie Thieblemont; Peter Lamprecht; Luc Mouthon; Sylvain Perruche; Véronique Witko-Sarsat
Journal:  J Clin Invest       Date:  2015-10-05       Impact factor: 14.808

2.  Increased monocyte transcription of the proteinase 3 gene in small vessel vasculitis.

Authors:  S Ohlsson; T Hellmark; K Pieters; G Sturfelt; J Wieslander; M Segelmark
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

3.  Transcription of proteinase 3 and related myelopoiesis genes in peripheral blood mononuclear cells of patients with active Wegener's granulomatosis.

Authors:  Chris Cheadle; Alan E Berger; Felipe Andrade; Regina James; Kristen Johnson; Tonya Watkins; Jin Kyun Park; Yu-Chi Chen; Eva Ehrlich; Marissa Mullins; Francis Chrest; Kathleen C Barnes; Stuart M Levine
Journal:  Arthritis Rheum       Date:  2010-06

4.  The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Authors:  Gheath Alatrash; Yoko Ono; Anna Sergeeva; Pariya Sukhumalchandra; Mao Zhang; Lisa S St John; Tian-Hui Yang; Kathryn Ruisaard; Paul M Armistead; Elizabeth A Mittendorf; Hong He; Na Qiao; Tania Rodriguez-Cruz; Shoudan Liang; Karen Clise-Dwyer; Eric D Wieder; Gregory Lizee; Sijie Lu; Jeffrey J Molldrem
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

5.  Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3.

Authors:  L Armstrong; S I H Godinho; K M Uppington; H A Whittington; A B Millar
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

6.  Proteinase 3 is an IL-32 binding protein.

Authors:  Daniela Novick; Menachem Rubinstein; Tania Azam; Aharon Rabinkov; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

7.  Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis.

Authors:  Holger Brockmann; Andreas Schwarting; Jörg Kriegsmann; Peter Petrow; Andreas Gaumann; Klaus-Michael Müller; Peter Robert Galle; Werner Mayet
Journal:  Arthritis Res       Date:  2002-03-27

8.  Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis.

Authors:  Masamoto Murakami; Takaaki Kaneko; Teruaki Nakatsuji; Kenji Kameda; Hidenori Okazaki; Xiuju Dai; Yasushi Hanakawa; Mikiko Tohyama; Akemi Ishida-Yamamoto; Koji Sayama
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.